Global Esophageal Cancer Market Report 2019: Merck's Keytruda Shows Utility in Subset of Esophageal Cancer
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals. The report estimates that in 2017, there were 488,800 incident cases of esophageal cancer worldwide, and expects that number to increase to 534,700 incident cases by 2026. Photofrin, a two-step therapy that involves the injection of the photoactive drug followed by drug activation using laser therapy, is the only FDA-approved drug for esophageal cancer. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91% of trials in Phase I-II, and only 9% in Phase III-IV.